Edit |   |
Antigenic Specificity | MAGE-1 (Target for Cancer Immunotherapy) |
Clone | [MZ2E/838] |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG1, kappa |
Format | unconjugated |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | Flow Cytometry (FC/FACS), Immunofluorescence (IF), Immunohistochemistry (IHC) Formalin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Recognizes a protein of 42-46kDa, identified as MAGE-1. This MAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, t |
Immunogen | Immunogen: Recombinant human MAGEA1 protein |
Other Names | [MZ2 E, cancer/testis antigen 1.1, CT1.1, MAGE1A, MAGEA1, Melanoma antigen family A 1, Melanoma associated antigen 1, Melanoma associated antigen MZ2 E], [MAGEA1; MAGEA1; CT1.1; MAGE1; MAGE1; MAGE1A; CT1.1] |
Gene, Accession # | [MAGEA1], Gene ID: 4100, NCBI: NP_004979.3, UniProt: P43355 |
Catalog # | MBS438965 |
Price | $190, $340, $340 |
Order / More Info | MAGE-1 (Target for Cancer Immunotherapy) Antibody from MYBIOSOURCE INC. |
Product Specific References | Kobayashi, Y., et al. 2000. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carci- noma. J. Hepatol. 32: 612-617 |